Medivir’s CEO: “We have attracted interest from the best investigators and hospitals to be part of the phase IIb study”

Medivir’s Q4 report summarises the major progress the company has made during 2024 in the development of drug candidate fostrox in combination with Lenvima for the treatment of advanced liver cancer. Now, the focus shifts to the upcoming phase IIb study, but what does the path forward look like? BioStock reached out to CEO Jens Lindberg for a comment.

Read the full interview with Jens Lindberg at biostock.se:

https://www.biostock.se/en/2025/02/medivirs-ceo-we-have-attracted-interest-from-the-best-investigators-and-hospitals-to-be-part-of-the-phase-iib-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/